Stock: Metropolis Healthcare
Research House: Nuvama
Advice: Buy
Stock Price: Rs 2,225
1-year Target Price: Rs 2,650
Potential Upside: 19.1%
Comment: Retain ‘buy’ as acquisition of Core Diagnostics will unlock synergies by enhancing cancer testing facilities and strengthening its presence in the North and East India. Also, the deal is reasonably valued and EPS accretive (in 2025-26 and 2026-27).
ET Wealth Edition: December 23-29
